Aspira Women's Health Inc. (Aspira) announced publication of a study on the use of its multivariate index assay, MIA2G (OVERA®), in the detection of ovarian cancer in Filipino women in the peer-reviewed International Journal of Environmental Research and Public Health. The paper, entitled: “Clinical Performance of a Multivariate Index Assay in Detecting Early-Stage Ovarian Cancer in Filipino Women,” highlights the first prospective study evaluating the clinical performance and overall utility of MIA2G (OVERA) ovarian cancer risk assessment in a non-White population. In the study, researchers prospectively compared various diagnostic methods, including ultrasound/IOTA (International Ovarian Tumor Analysis Rules), the biomarker CA-125, and OVERA, evaluating them for their ability to detect ovarian cancer.

Results were correlated with surgical findings. The data showed MIA2G (OVERA) to exhibit the best overall performance in detecting ovarian cancer with a sensitivity of 91.7%, regardless of menopausal status, compared to CA-125 with a sensitivity of 76.7%. Notably, MIA2G (OVERA) was shown to be more sensitive in detecting early-stage disease for this population.

MIA2G (OVERA) demonstrated 92.4% early-stage sensitivity vs CA-125 at 74.3%. The study also showed that MIA2G (OVERA) had the best overall performance of all individual classifiers, including in some of the most difficult to detect cancers cohorts such as premenopausal women, and early-stage disease. The study concluded that incorporating MIA2G (OVERA) rather than CA-125 into clinical assessment would increase the detection of early-stage ovarian cancers, regardless of menopausal status.